✉news ScienceSpace Policy first seen 1 d ago, last 1 d ago, peak #34
Vanda halts Novartis-originated social anxiety program after trial setback
Original: Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
Vanda Pharmaceuticals has stopped development of a social anxiety disorder program originally licensed from Novartis, following disappointing results in late-stage testing. The freeze ends a high-profile effort to bring a new treatment option to patients with social anxiety, and raises questions about Vanda's pipeline strategy going forward.
Why now: The late-stage failure of a licensed Novartis-originated drug candidate is a significant blow to Vanda's pipeline and investors are reacting.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/2377999